LOGIN
Latilactobacillus sakei LB-P12 Improves Symptoms in Mild Knee Osteoarthritis
October 2025
Latilactobacillus sakei LB-P12 Improves Symptoms in Mild Knee Osteoarthritis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial.
Sci Rep . 2025 Jul 17;15(1):25980.Synopsis
One hundred patients with mild knee osteoarthritis were randomized to receive Latilactobacillus sakei LB-P12, 10 billion CFU once daily (n=50), or identical placebo (n=50) for 12 weeks. The primary outcome was change in total WOMAC; secondary outcomes included WOMAC subscales (pain, stiffness, function), VAS pain, inflammatory markers (CRP, ESR, IL-1β, IL-6, TNF-α), COMP, radiographic joint space ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.